Construction for Long Non-Coding RNA (lncRNA)-Associated Competing Endogenous RNA (ceRNA) Network in Human Retinal Detachment (RD) with Proliferative Vitreoretinopathy (PVR)

ABCDEF Ke Yao
BDF Yixian Yu
AEF Hong Zhang

Corresponding Author: Hong Zhang, e-mail: tjyksys@163.com
Source of support: Departmental sources

Background: The aim of this study was to analyze the long non-coding RNA (lncRNA)-associated competing endogenous RNA (ceRNA) network in human retinal tissues following detachment with proliferative vitreoretinopathy (PVR).

Material/Methods: Expression data of 19 human detached retinas with PVR and 19 normal retinas from postmortem donors were downloaded from Gene Expression Omnibust (GEO) database (GSE28133). The R package “limma” was utilized to discriminate the dysregulated lncRNA and mRNA profiles. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of differentially expressed mRNAs were performed using R packages “Clusterprofiler.” The ceRNA network of dysregulated genes was constructed by using mircode, miRDB, miRTarBase and TargetScan databases, and was visualized by Cytoscape v3.6.1.

Results: A total of 23 lncRNAs and 994 mRNAs were identified significantly expressed between the human detached retinas with PVR and the normal retina tissues, with thresholds of |log₂FoldChange| >1.0 and adjusted P-value <0.05. The constructed ceRNA network (lncRNA-miRNA-mRNA regulatory axis) included 9 PVR-specific lncRNAs, as well as 27 miRNAs and 73 mRNAs.

Conclusions: We demonstrated the differential lncRNA expression profile and constructed a lncRNA-associated ceRNA network in human detached retinas with PVR. This may ferret out an unknown ceRNA regulatory network in human retinal detachment with PVR.

MeSH Keywords: Retinal Detachment • RNA, Long Noncoding • Vitreoretinopathy, Proliferative

Abbreviations: lncRNA – long non-coding RNA; ceRNA – competing endogenous RNA; miRNA – microRNA; RD – retinal detachment; PVR – proliferative vitreoretinopathy; GO – Gene Ontology; KEGG – Kyoto Encyclopedia of Genes and Genomes; GEO – Gene Expression Omnibust; PPI – protein–protein interaction

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/919871
Background

Retinal detachment (RD) occurs when the neurosensory retina layer separates from the retinal pigment epithelium. RD involving the foveal center can lead to profound loss of vision [1]. In most cases, RD occurs following a full thickness retinal break, allowing the ingress of fluid from the vitreous cavity to the subretinal space, which can result in retinal separation and is so-called “rhegmatogenous” [1,2]. A systematic review showed that rhegmatogenous RD incidence varied between 6.3 and 17.9 per 100,000 population, and was strongly associated with myopia, increasing age and certain vitreoretinal degenerations [3]. In addition to the loss of photoreceptors following RD, an inflammatory response also develops. RD triggers cell migration and proliferation and production of extracellular matrix proteins, which in turn results in the accumulation of vitreal and periretinal membranes, both hallmarks of proliferative vitreoretinopathy (PVR) [4]. In total, PVR occurs in 5–10% RD cases [5]. PVR can be detected during the late presentation of RD and complicate the post-operative period after a surgery for RD, leading to a re-detachment or limiting visual recovery [6,7]. Clinical studies using adjuvant therapy for the treatment of PVR have been conducted, including anti-inflammatory agents, anti-neoplastic/anti-proliferative agents, anti-growth factor pathway inhibitors and antioxidants, etc. [6,8–11]. However, the results are often contradictory or inconclusive with only limited success.

Long non-coding RNA (lncRNA) is a group of non-coding transcripts 200–10,000 bp in length but lacks significant protein-coding capacity. They interact in a regulatory manner before, during and after transcription [12]. Salmena et al. made a competing endogenous RNA (ceRNA) hypothesis that lncRNA, mRNA and other RNAs might act as microRNA (miRNA) sponges to inhibit miRNA function through sharing the miRNA response elements (MREs), which is a complicated post-transcriptional regulatory network [13]. There is much evidence to support this hypothesis [14–16]. On one hand, miRNAs can combine with their target mRNAs and inhibit their expression in the ceRNA network. On the other hand, lncRNA can regulate gene encoding protein level and following cell biology by competing with miRNAs [15,16]. Besides, each miRNA can influence up to hundreds of expressions of transcription, while each RNA transcription with different MREs can be targeted by multiple miRNAs [16,17].

In recent years, a growing number of studies have proven that the lncRNA-miRNA-mRNA regulation network is involved in the course of many diseases, including the tumors, Alzheimer disease and dermatitis etc. [12,16,18,19]. However, whether the ceRNA network takes part in human detached retinas with PVR has not been studied. Here, we downloaded expression data from Gene Expression Omnibus (GEO) database (GSE28133).

It contained 19 specimens from patients for severe retinal detachment with PVR and 19 normal control retina specimens from postmortem donors. Bioinformatics analysis and the ceRNA network were conducted to explore the pathological mechanism and potential therapeutic targets of retinal detachment with PVR.

Material and Methods

Tissue samples from the GEO database and bioinformatics analysis

The RNA expression data of tissue samples were obtained from GEO database. The dataset (GSE28133) contained 19 specimens from patients for severe retinal detachment with PVR and 19 normal control retina specimens from postmortem donors. Clinical and pathological features of patients were described [2]. All the samples were analyzed using Affymetrix Human Genome U133 Plus 2.0 Array.

Differentially expressed gene analysis

We used the “limma” package in R software to identify the differentially expressed genes (lncRNAs and mRNAs) between human detached retinas with PVR and the control group, with |log(FoldChange (FC))|>1.0 and adjusted P-value <0.05. Besides, mRNA and lncRNA annotation was performed using the Encyclopedia of DNA Elements (ENCODE) with ENSEMBL.

GO and KEGG functional enrichment analysis

To understand the potential biological functions and processes of differentially expressed genes, Gene Ontology database (GO, http://www.geneontology.org) and Kyoto Encyclopedia of Genes and Genomes (KEGG, http://www.kegg.jp), as well as the “clusterProfilerGO” package and “clusterProfilerKEGG” in R software, were utilized to perform GO and KEGG pathway analysis. Records with P-value <0.05 and enrichment >2.0 were preserved.

Construction of the lncRNA-miRNA-mRNA ceRNA and protein–protein interaction (PPI) networks

Based on the hypothesis that lncRNA could sponge the common miRNA and thus prevent miRNA from binding to their target genes [20], a ceRNA network was constructed. The mircode database (http://www.mircode.org/) was used for lncRNA to predict their targeted miRNAs. The miRNA-mRNA interactions were predicted by the mirTarBase (http://mirtarbase.mbc.nctu.edu.tw/), miRDB (http://www.mirdb.org/) and TargetScan (http://www.targetscan.org/). Finally, the predicted mRNAs were cross matched with the differentially expressed ones,
and the mRNA with no negatively regulated lncRNA or miRNA were abandoned. The lncRNA, miRNA and mRNA with log_{2}FC >1.0 and adjusted P-value <0.05 were preserved. Construction and visualization of the lncRNA-miRNA-mRNA ceRNA network were conducted using Cytoscape v3.6.1. Besides, PPI network of mRNAs involved in the ceRNA network was set up with high confidence (0.700) by String (https://string-db.org/).

Results

Differentially expressed lncRNAs and mRNAs between the human detached retinas with PVR and normal controls

Clinical characteristics of patients were described in the previous study [2]. In total, 994 genes were significantly changed between human detached retinas with PVR and normal human retinas with thresholds of log_{2}FC >1.0 and adjusted P-value <0.05, as is shown in the volcano map (Figure 1A). Among

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Yao K. et al.: LncRNA-associated ceRNA network in detached retinas © Med Sci Monit, 2020; 26: e919871

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
them, 23 genes were lncRNA, with 16 genes downregulated and 7 genes upregulated. The aberrantly expressed lncRNAs can be viewed in the heatmap (Figure 1B) and their gene IDs and log$_2$FC are listed (Table 1), in which the 9 lncRNAs taking part in the ceRNA network were marked with asterisk keys.

Besides, 971 mRNAs were identified as differentially expressed in which 655 (67.46%) were upregulated and 316 (32.54%) were downregulated. The differentially expressed mRNA levels were also presented in the heatmap (Figure 1C).

Functional enrichment analysis of differentially expressed mRNAs

GO and KEGG pathway analyses allow for the molecular function and signal pathway annotation of dysregulated mRNAs. Records with P-value <0.05 and enrichment >2.0 were preserved. The complete list of the 74 terms of GO analysis is presented in Supplementary Table 1. The top 20 GO terms were visualized in the bubble diagram and the most enriched pathways were the cell adhesion molecule binding (GO: 0050839), actin binding (GO: 0003779) and enzyme inhibitor activity (GO: 0004857), which contained 60, 49, and 44 genes respectively. As shown in Figure 2A), 13 GO terms of the top 20 took part in the binding function of the cell.

The KEGG pathway analysis indicated that 39 pathways were associated with differentially expressed mRNAs (Supplementary Table 2). The top 20 KEGG pathways enriched are visualized in the bubble diagram (Figure 2B). It shows that infection probably played an important role in retinal detachment with PVR, including human papillomavirus, Epstein-Barr virus, human cytomegalovirus, as well as tuberculosis, etc.

### Table 1. Dysregulated lncRNAs between human detached retinas with PVR and normal controls.

| lncRNA      | Gene ID | Expression change | logFC (PVR/N) | Adj. P-value |
|-------------|---------|-------------------|--------------|--------------|
| HCP5*       | 10866   | Up-regulation     | 1.947938297  | 1.53E-09     |
| LINC00623   | 72885   | Up-regulation     | 1.230129889  | 5.99E-08     |
| LINC01094   | 100505702 | Up-regulation    | 1.217325671  | 5.36E-06     |
| PSMB8-AS1   | 100507463 | Up-regulation    | 1.210172661  | 1.66E-16     |
| MIAT*       | 440823  | Down-regulation   | –1.031576283 | 1.01E-06     |
| CRNDE*      | 643911  | Up-regulation     | 1.048582535  | 9.62E-07     |
| BLACAT1     | 101669762 | Up-regulation    | 1.0105524554 | 1.51E-08     |
| ZNF571-AS1  | 100507433 | Down-regulation  | –1.06771719  | 0.000173     |
| AP000462*   | ---     | Down-regulation   | –1.08329906  | 4.33E-07     |
| SH3BP5-AS1  | 100506969 | Down-regulation  | –1.203614666 | 1.33E-07     |
| JPX*        | 554203  | Down-regulation   | –1.248531249 | 6.67E-06     |
| PGM5-AS1    | 572558  | Down-regulation   | –1.26206851  | 1.89E-05     |
| OTX2-AS1    | 100309464 | Down-regulation  | –1.383351463 | 1.96E-10     |
| RNF139-AS1  | 101927612 | Down-regulation  | –1.399211813 | 2.00E-05     |
| TDRG1*      | 732253  | Down-regulation   | –1.472180825 | 6.24E-09     |
| ELOVL2-AS1  | 100506409 | Down-regulation  | –1.613551017 | 1.38E-09     |
| LINC01137   | 728431  | Down-regulation   | –1.689264402 | 5.73E-09     |
| FAM13A-AS1* | 285512  | Down-regulation   | –1.774851965 | 1.87E-11     |
| SPAGS-AS1*  | 100506436 | Down-regulation  | –1.894825134 | 3.78E-10     |
| MIR124-2HG  | 100130155 | Down-regulation  | –2.035310985 | 1.55E-07     |
| AC005592*   | 101926975 | Down-regulation  | –2.175539179 | 4.42E-13     |
| RBFADN      | 100506070 | Down-regulation  | –2.290846454 | 1.01E-08     |

PVR – proliferative vitreoretinopathy; N – normal human retinas. * Represents the lncRNA taking part in the ceRNA network.
phagosome, focal adhesion, and complement and coagulation cascade were also suggested as participate in PVR progress, containing 32, 29, and 22 genes respectively.

Construction of a ceRNA network and PPI network in the human detached retinas with PVR

To further understand how lncRNA regulates mRNA through combining with miRNA in human detached retinas with PVR, a lncRNA-miRNA-mRNA (ceRNA) network was constructed. Consequently, we found that 9 lncRNAs interacted with the 27 miRNAs in the ceRNA network using the miRcode database (Table 2). A total of 1269 miRNA-targeted mRNAs based on the 27 miRNAs was predicted through miRDB, miRTarBase, and TargetScan databases. MiRNA-targeted mRNAs which were not contained in the differentially expressed mRNAs, which were discarded, and the 73 mutual mRNAs which were preserved (Figure 3A, Table 3). Finally, 9 lncRNAs, 27 miRNAs, and 73 mRNAs constituted the ceRNA network (Figure 4). Besides, KEEG pathways enriched by mRNAs in ceRNA network showed that most of them were bound with the PI3K-Akt signaling pathway and human cytomegalovirus infection (Figure 3B). The PPI network constructed for the 73 mRNAs furnished 21 genes with high confidence 0.700 (Figure 3C).

Discussion

PVR is known to complicate the post-operative period after a surgery for RD, leading to a re-detachment or limiting visual recovery. Traditional adjuvant therapy included anti-proliferative agents, anti-inflammatory agents, and anti-growth factor pathway inhibitors. But so far, studies for the treatment of PVR report limited success [6,8–11]. The previous study detected...
### Table 2. lncRNAs and specific targeted miRNAs in ceRNA network.

| lncRNA | miRNA                                      |
|-------|--------------------------------------------|
| TDRG1 | miR-17-5p, miR-20b-5p, miR-27a-3p, miR-125a-5p, miR-125b-5p |
| HCP5  | miR-137, miR-139-5p, miR-140-5p, miR-17-5p, miR-20b-5p, miR-216b-5p, miR-22-3p, miR-23b-3p, miR-24-3p, miR-363-3p, miR-1297, miR-27a-3p, miR-107, miR-425-5p, miR-125a-5p, miR-125b-5p, miR-10a-5p |
| JPX   | miR-301b-3p, miR-140-5p, miR-193a-3p, miR-216b-5p, miR-23b-3p, miR-24-3p, miR-363-3p, miR-449c-5p, miR-129-5p |
| MIAT  | miR-301b-3p, miR-139-5p, miR-140-5p, miR-17-5p, miR-20b-5p, miR-206, miR-613, miR-216b-5p, miR-22-3p, miR-23b-3p, miR-24-3p, miR-363-3p, miR-27a-3p, miR-107, miR-449c-5p, miR-125a-5p, miR-125b-5p, miR-10a-5p, miR-129-5p |
| SPAG5-AS1 | miR-17-5p, miR-20b-5p, miR-429, miR-217, miR-24-3p, miR-363-3p, miR-107, miR-425-5p |
| AC005592 | miR-139-5p, miR-17-5p, miR-20b-5p, miR-206, miR-613, miR-216b-5p, miR-107, miR-425-5p, miR-125a-5p, miR-125b-5p, miR-140-5p, miR-206, miR-613, miR-216b-5p, miR-107, miR-425-5p, miR-125a-5p, miR-125b-5p, miR-10a-5p, miR-129-5p |
| CRNDE | miR-140-5p, miR-142-3p, miR-193a-3p, miR-216b-5p, miR-217, miR-22-3p, miR-23b-3p, miR-363-3p, miR-27a-3p, miR-107, miR-449c-5p, miR-125a-5p, miR-125b-5p, miR-10a-5p, miR-129-5p |
| FAM13A-AS1 | miR-137, miR-139-5p, miR-142-3p, miR-17-5p, miR-20b-5p, miR-217, miR-22-3p, miR-23b-3p, miR-24-3p, miR-363-3p, miR-107, miR-449c-5p, miR-125a-5p, miR-125b-5p, miR-10a-5p, miR-129-5p |
| AP000462 | miR-17-5p, miR-20b-5p, miR-1297, miR-206, miR-613, miR-22-3p, miR-24-3p, miR-449c-5p, miR-1297 |

### Figure 3. mRNAs in ceRNA network. (A) Venn diagram of differentially expressed mRNAs in ceRNA network. (B) KEEG pathways enriched by mRNAs in ceRNA network. (C) The protein-protein interaction network constructed for mRNA involved in ceRNA network.
expression profile of 19 PVR patients and controls, but only focused on part of differentially expressed mRNAs [2]. Neither GO and KEGG functional analysis nor construction of ceRNA network were established. Thus, we re-analyzed the published microarray data of GEO database (GSE28133).

In our analysis, we found 971 mRNAs significantly differentially expressed in the human detached retinas with PVR compared to normal human retinas. The GO pathways enriched by the differentially expressed mRNA showed that main pathways of the top 20 took part in the binding function of the cell, such as cell adhesion molecule binding which contained CLIC1 (logFC=2.76), S100A11 (logFC=4.31) and ICAM1 (logFC=3.06), etc. Chloride intracellular channel 1 (CLIC1), and S100 calcium-binding protein A11 (S100A11) were positively correlated with cell proliferation, invasion, and migration and angiogenesis [21,22]. Intercellular adhesion molecule-1 (ICAM1) is involved in the adhesion of leukocytes to the blood vessel wall [23]. Such significantly dysregulated genes involved in cell adhesion and binding function may have an important role in PVR pathogenesis and deserve

| miRNA     | mRNA                              |
|-----------|-----------------------------------|
| miR-107   | VCAN, TGFBR3, GABRB1, ITGA2, LCOR, PLEKHF2, PCSK5 |
| miR-10a-5p| ELOVL2                             |
| miR-125a-5p| TMEM136, EIF4EBP1, MTUS1, TMEM136, STAT3, LIPA, EIF4EBP1 |
| miR-129-5p| SPRY4, C15                         |
| miR-1297  | ADM, CK52, MAN2A1                  |
| miR-137   | GLIPR1                             |
| miR-139-5p| LCOR, ZBTB34                       |
| miR-140-5p| LAMC1                             |
| miR-142-3p| EGR2, ZNF217, LCOR, MTUS1          |
| miR-17-5p | TMEM123, CDKN1A, PL51, NETO2, FIX1, CCND1, FAM57A, FAM129A, RAPGEF4, SLC16A9, CYBRD1, PPP3R1, PLEKHO2, CADM2, BTN3A1, STAT3, WEE1, TXNIP, SSX2IP, LCOR, TMEM138 |
| miR-183a-3p| LAMC1                             |
| miR-206   | GJA1, KCN21, CERS52, BDNF, SFRP1, WEE1 |
| miR-20b-5p| TXNIP, CADM2, RAPGEF4, CCND1, TMEM123, SLC16A9, PLEKHO2, FIX1, SSX2IP, STAT3, CYBRD1, PPP3R1, CDKN1A, PL51, BAMB1, NETO2, FAM129A |
| miR-216b-5p| SMAD1                             |
| miR-217   | NR4A2                             |
| miR-22-3p | RGS2, CSF1R                        |
| miR-23b-3p| GJA1                              |
| miR-24-3p | GB2A, SCML1, MLEC, ZNF217, ADD1, FSCN1 |
| miR-27a-3p| PPIF, TGFBR3, LPCAT1, PHLP2, PLXND1, ADD1, WEE1, ADORA2B |
| miR-301b-3p| GRB10, PRUN2E, TRPC3, IRF1         |
| miR-33a-3p| PPP3R1                            |
| miR-363-3p| CNNM4, PDNP, GPFT2, PHLP2, LHFP2   |
| miR-425-5p| LCOR, RAB31                       |
| miR-429   | TPD52L1                           |
| miR-449c-5p| MYC                              |
| miR-613   | CERS2, WEE1                        |

Table 3. miRNAs and specific targeted mRNAs in ceRNA network.
more exploration. The KEGG pathways showed that infection and Phosphoinositide 3-kinase (PI3K)-Akt signaling pathway come out in front in RD tissues with PVR. Cytomegalovirus, chlamydia trachomatis, and human immunodeficiency virus have been confirmed in many RD cases [24–27]. These are in conformance with our analysis and remind us of necessary etiological detection for tissues in vitreous cavity and possible targeted treatment. PI3K plays a crucial role as a mediator of growth factor signaling, cell proliferation, cell survival, and apoptotic inhibition. As the major component of the extracellular matrix in PVR, type I collagen was found to be regulated by the PI3K/Akt pathway in human retinal pigment epithelial cells [28]. Treatment targeting PI3K/Akt pathway to prevent PVR after surgery is worth being studied.

The miRNA is an extensive class of endogenous, noncoding and single-strand RNAs with 18–24 nucleotides that negatively regulates gene expression through interacting with the 3′-untranslated regions (3′UTR) of their target mRNAs [29]. Thus, miRNAs have essential roles in homeostasis and pathogenesis [29]. In the eye, various miRNAs could act on the retina and have an important role in neuroprotection and angiogenesis [30–32]. In our analysis, 27 miRNAs were predicted by the 9 lncRNAs in the ceRNA network using the miRcode database.
MiR-107, miR-125a-5p, miR-17-5p, miR-20b-5p, and miR-27a-3p interrelated with 7 or more protein-coding genes, which may play a more important role in ceRNA network. These aberrantly expressed miRNAs also played key roles in multiple biological processes of various diseases [33–35]. For example, miR-107 was reported to inhibit cell migration and invasion by modulating Notch2 expression and regulate autophagy and apoptosis by targeting TRAF3 [36,37]. However, the influence of these miRNAs on PVR is rarely explained.

Compared with protein-coding genes and miRNAs, lncRNAs have significant advantages as prognostic biomarkers or therapeutic targets [38,39]. LncRNA regulates gene encoding protein level and participates in the regulation of cell biology through competing with miRNAs in the ceRNA network. There were 23 lncRNAs that were detected to be significantly differentially expressed in the human detached retinas with PVR and 9 of them were involved in the ceRNA network. The most upregulated lncRNA in the ceRNA network is reported to be HCP5. HCP5 was reported to express mainly in the immune system and often considered to be associated with herpes zoster and cancers [40,41]. HCP5 can promote cancer via the PI3K/AKT pathway, which was found to be the most enriched in the KEGG pathways by miRNAs in the ceRNA network [40]. In our analysis, HCP5 was also predicted to interact with 16 miRNAs. Other notable lncRNAs in the ceRNA network reported have included TDRG1 and MIAT [42,43]. TDRG was reported to promote the proliferation and progression of cells through PI3K/Akt/mTOR signaling [42]. Targeting MIAT was found to protect against myocardial hypoxia/reoxygenation injury, but its function in RD and PVR has not been studied [43]. In addition, MALAT1 was also found to be significantly upregulated in the fibrovascular membranes and the peripheral blood samples of PVR patients. In vitro studies revealed a critical role of MALAT1 in RPE proliferation and migration [44]. However, studies that focus on the function of lncRNA as miRNA sponges in human RD and PVR are in deficiency.

Our analysis revealed how specific lncRNAs interact with miRNAs and mRNAs through the successful construction of a lncRNA-miRNA-mRNA network in human detached retinas with PVR. This may reveal unknown pathological mechanisms of RD with PVR, which may help to provide potential therapeutic targets. However, we did not conduct quantitative real-time polymerase chain reaction analysis to validate the results of our bioinformatics analysis. The results would be more convincing with such verification experiments.

**Conclusions**

We demonstrated the differential expression profiles of lncRNAs, and we constructed a lncRNA-associated ceRNA network in human retinal detachment with PVR. Our analysis may contribute to increased understanding of the pathogenesis of human retinal detachment with PVR and provide novel lncRNAs as potential therapeutic targets.

**Conflicts of interest**

None.

**Supplementary Table 1.** GO pathways enriched by the differentially expressed coding genes.

| ID          | Description                              | Count | P-value  |
|-------------|------------------------------------------|-------|----------|
| GO: 0005201 | Extracellular matrix structural constituent | 22    | 2.10E-11 |
| GO: 0005178 | Integrin binding                         | 26    | 1.92E-10 |
| GO: 0050839 | Cell adhesion molecule binding           | 60    | 2.62E-10 |
| GO: 0019838 | Growth factor binding                    | 26    | 2.98E-09 |
| GO: 003779  | Actin binding                            | 49    | 2.78E-08 |
| GO: 0042605 | Peptide antigen binding                  | 11    | 5.64E-08 |
| GO: 0061134 | Peptidase regulator activity             | 31    | 2.34E-07 |
| GO: 0004857 | Enzyme inhibitor activity                | 44    | 1.17E-06 |
| GO: 0061135 | Endopeptidase regulator activity         | 25    | 4.70E-06 |
| GO: 0048407 | Platelet-derived growth factor binding   | 6     | 6.50E-06 |
| GO: 0042277 | Peptide binding                          | 32    | 1.06E-05 |
| GO: 0033218 | Amide binding                            | 34    | 2.05E-05 |
| GO: 004866  | Endopeptidase inhibitor activity         | 23    | 2.51E-05 |
| ID         | Description                                      | Count | P-value  |
|------------|--------------------------------------------------|-------|----------|
| GO: 0051015 | Actin filament binding                           | 23    | 2.76E-05 |
| GO: 004548  | S100 protein binding                             | 6     | 3.70E-05 |
| GO: 005539  | glycosaminoglycan binding                        | 26    | 4.10E-05 |
| GO: 0002020 | Protease binding                                 | 19    | 4.63E-05 |
| GO: 0059201 | Heparin binding                                  | 21    | 5.65E-05 |
| GO: 0030414 | Peptidase inhibitor activity                     | 23    | 5.65E-05 |
| GO: 008191  | Metalloendopeptidase inhibitor activity          | 6     | 5.90E-05 |
| GO: 0015521 | Collagen binding                                 | 12    |           |
| GO: 0023026 | MHC class II protein complex binding             | 6     | 9.03E-05 |
| GO: 0031406 | Carboxylic acid binding                          | 23    | 0.000101 |
| GO: 001968  | Fibronectin binding                              | 7     | 0.000249 |
| GO: 0030507 | Spectrin binding                                 | 7     | 0.000249 |
| GO: 0050840 | Extracellular matrix binding                     | 10    | 0.000259 |
| GO: 008020  | G-protein coupled photoreceptor activity         | 5     | 0.000315 |
| GO: 003023  | MHC protein complex binding                      | 6     | 0.000366 |
| GO: 005518  | Fatty acid binding                               | 2     | 0.000411 |
| GO: 003051  | Protein binding, bridging                        | 20    | 0.000439 |
| GO: 0016504 | Peptidase activator activity                     | 8     | 0.000464 |
| GO: 005520  | Insulin-like growth factor binding               | 2     | 0.000517 |
| GO: 005546  | Phosphatidylinositol-4,5-bisphosphate binding    | 11    | 0.000544 |
| GO: 0019864 | IgG binding                                      | 5     | 0.000123 |
| GO: 0016641 | Oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor | 6 | 0.000133 |
| GO: 0004859 | Phospholipase inhibitor activity                 | 3     | 0.000202 |
| GO: 0019955 | Cytokine binding                                 | 15    | 0.000229 |
| GO: 0019524 | Carbohydrate binding                             | 7     | 0.000249 |
| GO: 0019525 | Carbohydrate binding                             | 7     | 0.000249 |
| GO: 005518  | Fatty acid binding                               | 2     | 0.000411 |
| GO: 0030574 | Protein binding, bridging                        | 20    | 0.000439 |
| GO: 0016504 | Peptidase activator activity                     | 8     | 0.000464 |
| GO: 000520  | Insulin-like growth factor binding               | 2     | 0.000517 |
| GO: 005546  | Phosphatidylinositol-4,5-bisphosphate binding    | 11    | 0.000544 |
| GO: 0019864 | IgG binding                                      | 5     | 0.000123 |
| GO: 0016641 | Oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor | 6 | 0.000133 |

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]
| ID          | Description                                | Count | P-value  |
|-------------|--------------------------------------------|-------|----------|
| GO: 0004197 | Cysteine-type endopeptidase activity       | 12    | 0.001529 |
| GO: 0013749 | FAD binding                                | 6     | 0.001673 |
| GO: 0050786 | RAGE receptor binding                       | 4     | 0.001676 |
| GO: 0043531 | ADP binding                                | 7     | 0.001704 |
| GO: 0060900 | Molecular adaptor activity                  | 20    | 0.001883 |
| GO: 0005507 | Copper ion binding                          | 9     | 0.00199  |
| GO: 0003785 | Actin monomer binding                        | 6     | 0.00206  |
| GO: 1901681 | Sulfur compound binding                     | 23    | 0.002196 |
| GO: 0098641 | Cadherin binding involved in cell-cell adhesion | 5   | 0.002201 |
| GO: 001540  | Amyloid-beta binding                        | 9     | 0.002258 |
| GO: 0036041 | Long-chain fatty acid binding               | 4     | 0.002413 |
| GO: 007396  | Cadherin binding                            | 29    |           |
| GO: 0043394 | Proteoglycan binding                        | 7     | 0.002799 |
| GO: 0031994 | Insulin-like growth factor i binding        | 4     | 0.003346 |
| GO: 0032561 | Guanylate nucleotide binding                | 33    | 0.003468 |
| GO: 0019001 | Guanylyl nucleotide binding                 | 33    | 0.003483 |
| GO: 0001848 | Complement binding                          | 5     | 0.003539 |
| GO: 0098631 | Cell adhesion mediator activity             | 7     | 0.003784 |
| GO: 0015297 | Antiporter activity                         | 11    | 0.003925 |
| GO: 008236  | Serine-type peptidase activity              | 25    | 0.004086 |

Supplementary Table 2. KEGG pathways enriched by the differentially expressed coding genes.

| ID          | Description                                | Count | P-value  |
|-------------|--------------------------------------------|-------|----------|
| hsa04744    | Phototransduction                          | 17    | 1.47E-14 |
| hsa05150    | Staphylococcus aureus infection            | 21    | 1.87E-10 |
| hsa04145    | Phagosome                                  | 32    | 2.46E-10 |
| hsa04610    | Complement and coagulation cascades         | 22    | 6.39E-10 |
| hsa05169    | Epstein-Barr virus infection               | 34    | 2.67E-08 |
| hsa05152    | Tuberculosis                               | 31    | 6.42E-08 |
| hsa05145    | Toxoplasmosis                              | 23    | 1.69E-07 |
| hsa05133    | Pertussis                                  | 18    | 3.54E-07 |
| hsa04612    | Antigen processing and presentation        | 18    | 4.37E-07 |
| hsa05140    | Leishmaniasis                              | 17    | 1.19E-06 |
| hsa05167    | Kaposi sarcoma-associated herpesvirus infection | 29 | 1.68E-06 |
| hsa05146    | Amoebiasis                                 | 19    | 3.14E-06 |
| hsa04512    | ECM-receptor interaction                    | 17    | 5.38E-06 |
| hsa04510    | Focal adhesion                             | 29    | 6.69E-06 |
| hsa04933    | AGE-RAGE signaling pathway in diabetic complications | 18 | 2.26E-05 |
| hsa04940    | Type I diabetes mellitus                   | 11    | 3.20E-05 |
| hsa05165    | Human papillomavirus infection             | 38    | 6.93E-05 |
| hsa05163    | Human cytomegalovirus infection            | 29    | 7.05E-05 |
| hsa04974    | Protein digestion and absorption           | 16    | 7.51E-05 |
| ID          | Description                                      | Count | P-value   |
|-------------|--------------------------------------------------|-------|-----------|
| hsa05134    | Legionellosis                                    | 12    | 7.74E-05  |
| hsa05164    | Influenza A                                      | 24    | 7.76E-05  |
| hsa05132    | Salmonella infection                             | 15    | 0.000157  |
| hsa05166    | Human T-cell leukemia virus 1 infection          | 27    | 0.000263  |
| hsa04514    | Cell adhesion molecules (CAMs)                   | 20    | 0.00035   |
| hsa05144    | Malaria                                          | 10    | 0.00054   |
| hsa04151    | PI3K-AKT signaling pathway                       | 37    | 0.00605   |
| hsa05170    | Human immunodeficiency virus 1 infection         | 25    | 0.000858  |
| hsa04210    | Apoptosis                                        | 18    | 0.01211   |
| hsa04380    | Osteoclast differentiation                       | 17    | 0.01518   |
| hsa04672    | Intestinal immune network for IgA production    | 9     | 0.002223  |
| hsa04670    | Leukocyte transendothelial migration             | 16    | 0.00352   |
| hsa05014    | Amyotrophic lateral sclerosis (ALS)              | 9     | 0.00296   |
| hsa04010    | MAPK signaling pathway                           | 30    | 0.002984  |
| hsa05120    | Cellular senescence                              | 19    | 0.00315   |
| hsa05130    | Pathogenic Escherichia coli infection            | 9     | 0.005004  |
| hsa04650    | Natural killer cell mediated cytotoxicity        | 16    | 0.005015  |
| hsa05160    | Hepatitis C                                      | 18    | 0.005171  |
| hsa00532    | Glycosaminoxyglycan biosynthesis – chondroitin sulfate/dermatan sulfate | 5 | 0.005557 |
| hsa04142    | Lysozyme                                         | 15    | 0.006575  |

References:

1. Wilkinson CP. Retinal detachment. 2014
2. Marie-No Le D, Wolfgang R, David M et al: Transcriptional analysis of human retinal detachment reveals both inflammatory response and photoreceptor death. PLoS One, 2011; 6(12): e28791
3. Mity D, Charteris DG, Fleck BW et al: The epidemiology of rhegmatogenous retinal detachment: geographical variation and clinical associations. Brit J Ophthalmol, 2009; 94(6): 678–84
4. Zandi S, Pfister IB, Traine PG et al: Biomarkers for PVR in rhegmatogenous retinal detachment. PLoS One, 2019; 14(4): e214674
5. Chaudhary R, Dretzke J, Scott R et al: Clinical and surgical risk factors in the development of proliferative vitreoretinopathy following retinal detachment surgery: A systematic review protocol. Syst Rev, 2016; 5(1): 107
6. Karayaka M, Albayrak S, Pehlivanoglu S et al: S-Fluorouracil added infusion fluid in patients with recurrent rhegmatogenous retinal detachment. Saud J Ophthalmol, 2019; 33: 56–60
7. Lauro SD, Kadhim MR, Charteris DG, Pastor JC: Classifications for proliferative vitreoretinopathy (PVR). An analysis of their use in publications over the last 15 years. J Ophthalmol, 2016; 2016: 7807596
8. Wickham L, Bunce C, Wong D et al: Randomized controlled trial of combined S-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology, 2007; 114(4): 698–704
9. Hamid A, Mostafa F, Homa T et al: Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: A randomized clinical trial. Ophthalmology, 2008; 115(11): 1938–43
10. Pastor JC, Rojas J, Pastor-Iodate S et al: Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res, 2016; 51: 125–55
11. Cheema RA, Peyman GA, Fang T et al: Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging, 2007; 38(5): 365–70
12. Xu S, Sui J, Yang S et al: Integrative analysis of competing endogenous RNA network focusing on long noncoding RNA associated with progression of cutaneous melanoma. Cancer Med-Us, 2018; 7(4): 1019–29
13. Salmena L, Poliseno L, Tay T et al: ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell, 2011; 146(3): 353–58
14. Laura P, Leonardo S, Jiangwen Z et al: A coding-independent function of gene and pseudogene miRNAs regulates tumour biology. Nature, 2015; 465(7301): 1033–38
15. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell, 2009; 136(2): 215–33
16. Li F, Huang C, Li Q, Wu X: Construction and comprehensive analysis for dysregulated long non-coding RNA (IncRNA)-associated competing endogenous RNA (ceRNA) network in gastric cancer. Med Sci Monit, 2018; 24: 37–49
17. Karreth FA, Pandolfi PP: ceRNA Cross-talk in cancer: Ehen ce-bling rivalries go awry. Cancer Discov, 2013; 3(10): 1113–21
18. Wang Z, Xu P, Chen B et al: Identifying circRNA-associated- ceRNA networks in the hippocampus of Aβ1–42-induced Alzheimer’s disease-like rats using microarray analysis. Aging, 2018; 10(4): 775–88
19. Wang X, Bao K, Wu P et al: Integrative analysis of IncRNAs, miRNAs, and mRNA-associated ceRNA network in an atopic dermatitis recurrence model. Int J Mol Sci, 2018; 19(10): 3263
20. Jiang T, Guo J, Hu Z et al: Identification of potential prostate cancer-related pseudogenes based on competitive endogenous RNA (ceRNA) network hypothesis. Med Sci Monit, 2018; 24: 4213–19
20. Feng J, Xu J, Xu Y et al: CLIC1 promotes the progression of oral squamous cell carcinoma via integrins/ERK pathways. Am J Transl Res, 2019; 11(2): 557–71
21. Takamatsu H, Yamamoto K, Tomonobu N et al: Extracellular S100A11 plays a critical role in spread of the fibroblast population in pancreatic cancers. Oncol Res, 2019; 27(6): 713–27
23. Sarecka-Hujar B, Zak I, Krauze J: Interactions between rs5498 polymorphism in the ICAM1 gene and traditional risk factors influence susceptibility to coronary artery disease. Clin Exp Med, 2009; 9(2): 117–24

24. Boiko EV, Pozniak AL, Suetov AA et al.: [Role of Chlamydia trachomatis intraocular infection in the development of proliferative vitreoretinopathy (experimental study).] Vestn Oftalmol, 2015; 131(1): 50–57 [in Russian]

25. Papakostas TD, Vaavas D: Postoperative complications of scleral buckling. Ophthalmology, 2017; 33(1): 70–74

26. Kunavisarut P, Vavvas D: Postoperative complications of scleral buckling. Ophthalmology, 2017; 33(1): 70–74

27. Papakostas TD, Vaavas D: Postoperative complications of scleral buckling. Ophthalmology, 2017; 33(1): 70–74

28. Yokoyama K, Kimoto K, Itoh Y et al.: The PI3K/Akt pathway mediates the expression of type I collagen induced by TGF-β2 in human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol, 2012; 250(1): 15–23

29. Kaneko H, Terasaki H: Biological involvement of microRNAs in proliferative vitreoretinopathy. Transl Vis Sci Techn, 2017; 6(4): 5

30. Yoon C, Kim D, Kim S et al.: MiR-9 regulates the post-transcriptional level of VEGF165a by targeting SRPK-1 in ARPE-19 cells. Graefes Arch Clin Exp Ophthalmol, 2012; 250(1): 15–23

31. Ye E, Steinle JJ: miR-15b/16 protects primary human retinal microvascular endothelial cells against hyperglycemia-induced increases in tumor necrosis factor alpha and suppressor of cytokine signaling 3. J Neuroinflamm, 2015; 12(1): 44

32. Garcia JG, Verin AD, Schaphorst K et al.: Regulation of endothelial cell myosin light chain kinase by Rho, cortactin, and p60(src). Am J Physiol, 1999; 276(6): L1899–98

33. Yang X, Qiu J, Kang H et al.: miR-125a-5p suppresses colorectal cancer progression by targeting VEGF. Cancer Manag Res, 2018; 10: 5839–53

34. Zhang D, Yi Z, Fu Y: Downregulation of miR-20b-5p facilitates Mycobacterium tuberculosis survival in RAW 264.7 macrophages via attenuating the cell apoptosis by Mcl-1 upregulation. J Cell Biochem, 2019; 120(4): 5889–96

35. Ding J, Cheng Y, Zhang Y et al.: The miR 27a 3p/USP25 axis participates in the pathogenesis of recurrent miscarriage by inhibiting trophoblast migration and invasion. J Cell Physiol, 2019; 234(11): 19951–63

36. Chen L, Chen X, Zhang R et al.: MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression. J Neurooncol, 2013; 112(1): 59–66

37. Zhao X, Li H, Wang L: MicroRNA-107 regulates autophagy and apoptosis of osteoarthritis chondrocytes by targeting TRAF3. Int Immunopharmacol, 2019; 71: 181–87

38. Chandra GS, Nandan TY: Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int J Cancer, 2017; 140(9): 1955–67

39. Hauptman N, Glavač D: Long non-coding RNA in cancer. Int J Mol Sci, 2013; 14(3): 4655–69

40. Liu Y, Helms C, Liao W et al.: A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet, 2008; 4(3): e1000041

41. Liu N, Zhang R, Zhao X et al.: A potential diagnostic marker for ovarian cancer: Involvement of the histone acetyltransferase, human males absent on the first. Oncol Lett, 2013; 6(2): 393–400

42. Gan Y, Wang Y, Tan Z et al.: TDRG1 regulates chemosensitivity of seminoma TCam-2 cells to cisplatin via PI3K/Akt/mTOR signaling pathway and mitochondria-mediated apoptotic pathway. Cancer Biol Ther, 2016; 17(7): 741–50

43. Chen L, Zhang D, Yu L, Dong H: Targeting MIA40 reduces apoptosis of cardiomyocytes after ischemia/reperfusion injury. Bioengineered, 2019; 10(1): 121–32

44. Zhou RM, Wang XQ, Yao J et al.: Identification and characterization of proliferative retinopathy-related long noncoding RNAs. Biochem Biophys Res Commun, 2015; 465(3): 324–30